Antimicrobials 2020 would like to thank the following sponsors for their support:


Platnum Sponsor


For more than a century, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Today, MSD continues to be at the forefront of research to deliver innovative health solutions and advance the prevention and treatment of diseases that threaten people and animals around the world.

Silver Sponsors 


We are an innovative medical technology company primarily focused on improving women’s health and wellbeing through early detection and treatment. Our purpose is to enable healthier lives everywhere, every day.Our game-changing diagnostic, detection, surgical and medical aesthetic products are designed to diagnose and treat patients earlier and more effectively.

As global champions of women’s health, we bring The Science of Sure® to life by helping healthcare professionals minimise doubt and maximise the confidence in their decisions and diagnoses


Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid and actionable test results are needed most, in fields such as critical and health- care associated infections, sexual health, genetic diseases and cancer.

Bronze Sponsors

 Abbott is a global leader in rapid diagnostic tests that deliver the right care, at the right time. Our comprehensive portfolio of   tests provide fast, reliable and actionable information that helps improve quality of care and enables better clinical and   economic health outcomes. For more information, visit www.alere.com.au




Australian Safety and Quality in Health Care Commission

The Commission's purpose is to contribute to better health outcomes and experiences for all patients and consumers, and improved value and sustainability in the health system by leading and coordinating national improvements in the safety and quality of health care. Within this overarching purpose the Commission aims to ensure people are kept safe when they receive health care and that they receive the health care they should.

The Commission works in four priority areas:

  • Patient safety
  • Partnering with patients, consumers and communities
  • Quality, cost and value
  • Supporting health professionals to provide care that is informed, supported and organised to deliver safe and high-quality care.

The Commission is a corporate Commonwealth entity and part of the Health portfolio of the Australian Government. As such, it is accountable to the Australian Parliament and the Minister for Health. In 2006, the Council of Australian Governments (COAG) established the Commission to lead and coordinate national improvements in the safety and quality of health care. The Commission’s permanent status was confirmed with the passage of the National Health and Hospitals Network Act 2011, while its role was codified in the National Health Reform Act 2011. The Commission commenced as an independent statutory authority on 1 July 2011, funded jointly by the Australian Government and by state and territory governments.



BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics, and delivery of care. In diagnostics, BD supplies instrumentation and consumables for Microbiology, Molecular and Cytology testing, and is a leading provider of products for the safe collection and transport of diagnostic specimens. Major BD Diagnostics brands include BD KiestraTM, BD BACTECTM, BD BACTEC MGITTM, BD PhoenixTM, BD ViperTM, BD MAXTM, BD SurePathTM, and BD Vacutainer®. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. In 2017, BD welcomed C.R. Bard and its products into the BD family. For more information on BD, please visit http://bd.com


As a world leader in the field of in vitro diagnostics, bioMérieux continues its commitment to improving healthcare worldwide through a complete range of in-vitro diagnostic solutions for managing Infectious and Cardiovascular diseases. Biofire has strengthened our leadership position in moelcular diagnostics and syndromic testing and we continue to innovate and design the diagnostics of the future, whilst improving laboratory efficiency and turnaround time for the benefit of the patient. Our partnership with COPAN and the distribution of the WASP and WASPLab enhances this commitment further. 

The Mérieux family's commitment to serving human and animal health worldwide has always been handled within the single concept of "One Health". In the field of antimicrobial resistance, such a holistic approach is especially important, and bioMérieux's product and service offer includes the characterisation of microbial flora, detection of specific pathogens, antibiotic resistance profiling, as well as analysis of food, drug, water, and air samples in the clinical, veterinary and food sectors. bioMérieux is also a long-standing international advocate for awareness-raising activities related to antibiotic resistance. It has produced a wide array of educational materials, increased its sponsorship for scientific studies and organisations, and continues to communicate actively about the global antibiotic resistance threat.


 At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive  to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. 

For more than 150 years, Pfizer has worked to make a difference for all who rely on us. 

Mayne Pharma 


Mayne Pharma is a specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide. 

Maybe Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world, including Kapanol® (sustained-release morphine used to treat chronic pain), Doryx® (delayed-release doxycycline hyclate used to treat bacterial infections) and Lozanoc® (super bioavailable intraconazole used to treat fungal infections). Furthermore, Mayne Pharma in-licenses novel treatments for Australian patients such as the recently launched Monurol® (fosfomycin trometamol), a single dose antibiotic for uncomplicated cystitis.

Mayne Pharma is committed to looking after the health of Australians with more than $110 million invested in R&D over the last 5 years, and we will continue to listen and respond to the needs of local health care professionals


QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further information can be found at http://www.qiagen.com.